23andMe reported new genetic findings tied to outcomes and side effects from GLP-1 receptor agonist therapies. In a Nature study, investigators analyzed 27,885 research-consented participants and identified variants in GLP1R linked to enhanced weight-loss response, alongside variants in GLP1R and GIPR associated with nausea and vomiting. The company framed the results as direct genetic evidence that differences in drug target genes can explain inter-person variability. While the identified effect sizes were described as modest, the researchers propose a foundation for precision approaches that could stratify patients in advance for efficacy and tolerability. Separately, the dataset also aligns with a broader clinical interest in biomarkers that can predict response to incretin-based obesity treatments, potentially informing prescribing and expectations.